MedTrace Logo

Evaluation of the Hypolipidemic Effect of Bergavit by a Human Trial.

NCT06692777 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-11-18

No results posted yet for this study

Summary

Bergavit is a product contains bergamot. Bergamot is an endemic plant of the Calabrian region in southern Italy with a unique profile of flavonoids and flavonoid glycosides present in its juice and albedo, its flavonoids was able to reduce serum levels of lipids and ameliorate the thickening of the arteries through modulating enzymatic activities, anti-oxidation, anti-inflammatory mechanisms and inhibition of monocyte activation and proliferation.The primary outcome of the study the assessment of the the hypolipidemic effect of Bergavit. The secondary outcomes are the assessment of: a) the hypoglycemic effect of Bergavit, b) the activity of Bergavit on weight loss, and c) the hepatoprotective activity of Bergavit.

Conditions

Interventions

DIETARY_SUPPLEMENT

Bergavit

Subjects treated with Bergavit capsule intake of 150 mg/die of pure flavonoids for 4 months.

DIETARY_SUPPLEMENT

Placebo

Subjects will take capsule equivalent amount of maltodextrin for 4 months.

Sponsors & Collaborators

  • Chung Shan Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-21
Primary Completion
2024-09-30
Completion
2024-10-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06692777 on ClinicalTrials.gov